Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: migalastat hydrochloride, migalastat | 1.00 |
| trials ClinicalTrials.gov | 41 Parkinson's trials, 2 stopped | 0.96 |
| literature PubMed | 37 Parkinson's papers of 6,860 | 0.52 |
| pathways Reactome | 2 pathways; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 5492
Sealed predictions
- GLA in dopamine neurons, braak-0.32 (p 0.402) → +0.31 (p 0.416)receipt 5502
Swarm cases
receipt 5502: GLA in dopamine neurons, braak
- power
- full sample -0.01 (p 0.969, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.949, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.935, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.13, sign flips 6; without severely affected donors -0.01 (p 0.969, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GLA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts